Acadian Asset Management’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-36
| Closed | – | – | 2433 |
|
|
2020
Q3 | $0 | Sell |
36
-76,274
| -100% | -$725K | ﹤0.01% | 2458 |
|
|
2020
Q2 | $584K | Sell |
76,310
-24,441
| -24% | -$187K | ﹤0.01% | 1145 |
|
|
2020
Q1 | $623K | Sell |
100,751
-99,064
| -50% | -$873K | ﹤0.01% | 915 |
|
|
2019
Q4 | $2.43M | Sell |
199,815
-242,079
| -55% | -$2.65M | 0.01% | 626 |
|
|
2019
Q3 | $5.1M | Sell |
441,894
-477,170
| -52% | -$5.02M | 0.02% | 466 |
|
|
2019
Q2 | $9.18M | Buy |
919,064
+236,984
| +35% | +$2.56M | 0.04% | 292 |
|
|
2019
Q1 | $8.79M | Buy |
682,080
+139,134
| +26% | +$2.07M | 0.04% | 327 |
|
|
2018
Q4 | $8.25M | Sell |
542,946
-66,022
| -11% | -$1.26M | 0.04% | 299 |
|
|
2018
Q3 | $12.2M | Buy |
608,968
+95,955
| +19% | +$2.18M | 0.05% | 260 |
|
|
2018
Q2 | $10M | Buy |
513,013
+328,331
| +178% | +$7.26M | 0.04% | 300 |
|
|
2018
Q1 | $3.72M | Sell |
184,682
-314,934
| -63% | -$5.33M | 0.02% | 457 |
|
|
2017
Q4 | $6.62M | Sell |
499,616
-398,359
| -44% | -$6.01M | 0.03% | 329 |
|
|
2017
Q3 | $16.6M | Sell |
897,975
-325,542
| -27% | -$6.07M | 0.07% | 218 |
|
|
2017
Q2 | $22.5M | Sell |
1,223,517
-3,173
| -0.3% | -$62.9K | 0.1% | 184 |
|
|
2017
Q1 | $27.7M | Buy |
1,226,690
+1,086,937
| +778% | +$26M | 0.13% | 162 |
|
|
2016
Q4 | $4.86M | Buy |
139,753
+135,233
| +2,992% | +$4.04M | 0.02% | 421 |
|
|
2016
Q3 | $111K | Buy |
4,520
+777
| +21% | +$19.4K | ﹤0.01% | 1048 |
|
|
2016
Q2 | $90K | Buy |
+3,743
| New | +$85.8K | ﹤0.01% | 1052 |
|
Acadian Asset Management's AMAG Position: Q4 2020 in Review
Acadian Asset Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 36 shares.
Acadian Asset Management first reported a position in AMAG in Q2 2016 and held it in 18 quarters. The position peaked at $27.7M in Q1 2017. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Acadian Asset Management reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Acadian Asset Management sold 36 AMAG Pharmaceuticals shares in Q4 2020.
- Acadian Asset Management first reported a position in AMAG Pharmaceuticals in Q2 2016 and held it in 18 quarters.
- Acadian Asset Management's AMAG Pharmaceuticals position peaked at $27.7M in Q1 2017.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Acadian Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.